Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 25 August 1997.
"We have enjoyed a very good relationship with the American Red Cross for several years. The commitment to a long-term contract was initiated by CEL- SCI based upon early results from the Company's clinical trials with Multikine. We are pleased to be working with the American Red Cross," says Geert Kersten, Chief Executive Officer of CEL-SCI Corporation.
Multikine is a natural mixture of human immune system regulators called cytokines. It contains Interleukin -2 and other cytokines, several of which are being investigated individually as potential HIV -1 and cancer treatments. The product is currently in four (4) clinical trials against HIV, prostate cancer and head and neck cancer.
The American Red Cross is the nation's preeminent provider of blood and blood products. CEL-SCI Corporation is a pioneer in the field of natural immunotherapy . The Company is developing immune based treatments for cancer, AIDS, tuberculosis, malaria and herpes simplex.
CEL-SCI press releases are available through Company News On-Call by fax, 800-758-5804, Ext. 445563, or at http://www.prnewswire.com on the Internet.
When used in this report, the words "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected.
Factors that could cause or contribute to such differences include, an inability to duplicate the clinic results demonstrated in preclinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 1996. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
CONTACT: Geert Kersten, Chief Executive Officer of CEL-SCI Corporation, 703-549-5293/
Copyright (c) 1997/PR NewsWire. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, PR Newswire, 810 Seventh Avenue, New York, NY 10019.
970825
PR970818
Copyright © 1997 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .